PKP2 arrhythmogenic cardiomyopathy (PKP2-acm)

Clinical trials for PKP2 arrhythmogenic cardiomyopathy (PKP2-acm) explained in plain language.

Never miss a new study

Get alerted when new PKP2 arrhythmogenic cardiomyopathy (PKP2-acm) trials appear

Sign up with your email to follow new studies for PKP2 arrhythmogenic cardiomyopathy (PKP2-acm), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 1

One-Time gene infusion aims to fix inherited heart disease

Disease control Recruiting now

This early-stage trial tests a single intravenous dose of a gene therapy called RP-A601 in 9 adults with a genetic heart condition (PKP2-ACM) that causes dangerous heart rhythms and heart failure. The therapy delivers a working copy of the PKP2 gene to heart cells to restore prot…

Matched conditions: PKP2 ARRHYTHMOGENIC CARDIOMYOPATHY (PKP2-ACM)

Phase 1 • Sponsor: Rocket Pharmaceuticals Inc. • Aim: Disease control

Last updated Jun 27, 2026 12:08 UTC

PKP2 arrhythmogenic cardiomyopathy (PKP2-acm)

Get alerted when new PKP2 arrhythmogenic cardiomyopathy (PKP2-acm) trials appear

One-Time gene infusion aims to fix inherited heart disease